ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model

Heskamp, Sandra; Laarhoven, Hanneke W. M. van; Molkenboer-Kuenen, Janneke D.M.; Franssen, Gerben M.; Versleijen-Jonkers, Yvonne M.H.; Oyen, Wim J.G.; Graaf, Winette T.A. van der; Boerman, Otto C.

doi:10.2967/jnumed.110.075648

Cited by 79 publications

(82 citation statements)

References 37 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is caused by the abnormal architecture of tumor vasculature, lack of effective lymphatic drainage, and the production of vascular mediators such as VEGF, which enhance the extravasation and accumulation of macromolecules into tumor tissue (27). The levels of nonspecific uptake observed with PD-L1.3.1 in MCF-7 and MDA-MB-231 xenografs are in the same range as those observed with other antibodies and in other antigen-negative xenograft models (28)(29)(30).…”

Section: Discussionsupporting

confidence: 65%

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

et al. 2015

Self Cite

View full text Add to dashboard Cite

Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive antitumor activity. Patients with tumors expressing PD-L1 are most likely to respond to this treatment. The aim of our study was to develop a noninvasive imaging technique to determine tumor PD-L1 expression in vivo. This could allow selection of patients that are most likely to benefit from anti-PD-1/PD-L1 treatment and to monitor PD-L1 expression during therapy. The monoclonal antibody PD-L1.3

show abstract

Section: Discussionsupporting

confidence: 65%

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this way, not only the level of a molecular target in the tumour, but also its accessibility to proposed therapy might be evaluated [16,30,31]. However, slow clearance from blood and organs in equilibrium with blood requires several (three-to-seven) days between injection of the probe and measurement, to obtain a reasonably high tumour-to-blood ratio.…”

Section: Discussionmentioning

confidence: 99%

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

Orlova

Hofström

Strand

et al. 2012

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Determination of the BCM Five sections (4 μm) of paraffinembedded pancreases, 100 μm apart from each other, were stained with an anti-insulin antibody (4 μg/ml in PBS containing 1% BSA w/v) (sc 9168; Santa Cruz Biotechnology, Santa Cruz, CA, USA) as previously described [20].…”

Section: Methodsmentioning

confidence: 99%

Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin

et al. 2014

Self Cite

View full text Add to dashboard Cite

Aims/hypothesis A reliable method for in vivo quantification of pancreatic beta cell mass (BCM) could lead to further insight into the pathophysiology of diabetes. The glucagonlike peptide 1 receptor, abundantly expressed on beta cells, may be a suitable target for imaging. We investigated the potential of radiotracer imaging with the GLP-1 analogue exendin labelled with indium-111 for determination of BCM in vivo in a rodent model of beta cell loss and in patients with type 1 diabetes and healthy individuals. MethodsThe targeting of 111 In-labelled exendin was examined in a rat model of alloxan-induced beta cell loss. Rats were injected with 15 MBq 111 In-labelled exendin and single photon emission computed tomography (SPECT) acquisition was performed 1 h post injection, followed by dissection, biodistribution and ex vivo autoradiography studies of pancreatic sections. BCM was determined by morphometric analysis after staining with an anti-insulin antibody. For clinical evaluation SPECT was acquired 4, 24 and 48 h after injection of 150 MBq 111 In-labelled exendin in five patients with type 1 Maarten Brom and Wietske Woliner-van der Weg contributed equally to this study. Diabetologia (2014) 57:950-959 DOI 10.1007 diabetes and five healthy individuals. The tracer uptake was determined by quantitative analysis of the SPECT images. Results In rats, 111 In-labelled exendin specifically targets the beta cells and pancreatic uptake is highly correlated with BCM. In humans, the pancreas was visible in SPECT images and the pancreatic uptake showed high interindividual variation with a substantially lower uptake in patients with type 1 diabetes. Conclusions/interpretation These studies indicate that 111 Inlabelled exendin may be suitable for non-invasive quantification of BCM.

show abstract

ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model

Cited by 79 publications

References 37 publications

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin

Contact Info

Product

Resources

About